Diane E. Sullivan
Known title: DirectorCIK: 0001968736
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.
Transaction History
| LXRX | ▲ Buy | Option Exercise | 89,312 | $0 | 6/3/2026 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 838 | — | 4/18/2026 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 403 | $6K | 4/18/2026 | View on chart |
| LXRX | ▲ Buy | Option Exercise | 36,810 | $0 | 5/13/2025 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 838 | — | 4/18/2025 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 437 | $4K | 4/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis
Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis. Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.